What is the share price of Sun Pharmaceutical Industries Ltd (SUNPHARMA) today?
The share price of SUNPHARMA as on 14th July 2026 is ₹1925.30. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The past returns of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share are- Past 1 week: 0.87%
- Past 1 month: 5.69%
- Past 3 months: 16.29%
- Past 6 months: 11.15%
- Past 1 year: 14.19%
- Past 3 years: 78.63%
- Past 5 years: 181.32%
What are the peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA)?
The peers or stocks similar to Sun Pharmaceutical Industries Ltd (SUNPHARMA) include:What is the dividend yield % of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The current dividend yield of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 0.83.What is the market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹461008.22 Cr as of 14th July 2026.What is the 52 week high and low of Sun Pharmaceutical Industries Ltd (SUNPHARMA) share?
The 52-week high of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is ₹1953.90 and the 52-week low is ₹1548.What is the PE and PB ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) stock?
The P/E (price-to-earnings) ratio of Sun Pharmaceutical Industries Ltd (SUNPHARMA) is 40.16. The P/B (price-to-book) ratio is 5.50.Which sector does Sun Pharmaceutical Industries Ltd (SUNPHARMA) belong to?
Sun Pharmaceutical Industries Ltd (SUNPHARMA) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares?
You can directly buy Sun Pharmaceutical Industries Ltd (SUNPHARMA) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Sun Pharmaceutical Industries Ltd
SUNPHARMA Share Price
NSESUNPHARMA Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
SUNPHARMA Performance & Key Metrics
SUNPHARMA Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 40.16 | 5.50 | 0.83% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 43.55 | 6.17 | 0.52% |
from 32 analysts
Price Upside
Earnings Growth
Rev. Growth
SUNPHARMA Company Profile
Sun Pharmaceutical Industries Limited is a pharmaceuticals company which offers generics, branded generics, specialty products, over-the-counter products, anti-retroviral and APIs.
SUNPHARMA Sentiment Analysis
SUNPHARMA Sentiment Analysis
SUNPHARMA Stock Summary · May 2026
Management framed the transaction as a transformative, scale‑creating acquisition that will be EPS‑accretive from day one and is priced at $14.00 per share (about $3.99 billion equity value) with pro‑forma leverage of roughly 2.3x EBITDA. They stressed preserving Organon’s strengths—a roughly 30% EBITDA margin, a ~50‑brand women's‑health portfolio and global manufacturing footprint—while prioritizing cost synergies (targeting about $350 million over two to four years), commercial cross‑selling, selective in‑licensing of pre‑LOE biosimilars and pre‑close regulatory filings to accelerate launches. Management described an integration approach focused on diagnostic assessment, two‑way learning, talent retention and an integration office, and signaled priority on early deleveraging using expected combined free cash flow of about $2.0–$2.5 billion. At the same time they acknowledged tensions including Organon’s limited organic growth and pipeline, balance‑sheet and refinancing considerations tied to roughly $8.5 billion gross debt, and US biosimilars regulatory uncertainty, and they said several disclosure details will be finalized closer to closing; they expect to seek approvals and aim to close in roughly six to nine months.
SUNPHARMA Stock Growth Drivers
SUNPHARMA Stock Growth Drivers
6Transformational acquisition driving scale and higher‑value mix
Management frames the Organon transaction as a transformational step that materially increases Sun Pharma’s scale
High‑quality established brands and women’s‑health leadership
Organon brings a deep, defendable established‑brand franchise and clear leadership in women’s health that strengthens
SUNPHARMA Stock Challenges
SUNPHARMA Stock Challenges
4Material increase in leverage and refinancing/interest-rate exposure
The transaction will move the company from a net-cash position to a pro-forma net-debt/EBITDA of
Synergy and cash-generation assumptions are preliminary and execution-dependent
The company cites roughly $350 million of synergies to be realized over two to four
SUNPHARMA Forecast
SUNPHARMA Forecasts
Price
Revenue
Earnings
SUNPHARMA Share Price Forecast
SUNPHARMA Share Price Forecast
All values in ₹
All values in ₹
SUNPHARMA Company Revenue Forecast
SUNPHARMA Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
SUNPHARMA Stock EPS (Earnings Per Share) Forecast
SUNPHARMA Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
SUNPHARMA
SUNPHARMA
Income
Balance Sheet
Cash Flow
SUNPHARMA Income Statement
SUNPHARMA Income Statement
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 12,630.90 | 12,588.84 | 13,185.30 | 13,645.39 | 14,141.08 | 13,571.71 | 14,315.86 | 14,948.23 | 16,099.38 | 15,070.29 | ||||||||||
| Operating & Other expenses | 8,973.68 | 9,049.39 | 9,045.13 | 9,352.43 | 9,982.61 | 9,604.43 | 10,367.74 | 9,951.26 | 11,061.53 | 10,657.59 | ||||||||||
| EBITDA | 3,657.22 | 3,539.45 | 4,140.17 | 4,292.96 | 4,158.47 | 3,967.28 | 3,948.12 | 4,996.97 | 5,037.85 | 4,412.70 | ||||||||||
| Depreciation/Amortization | 622.14 | 650.36 | 655.13 | 625.91 | 630.56 | 663.79 | 700.55 | 729.50 | 732.33 | 775.47 | ||||||||||
| PBIT | 3,035.08 | 2,889.09 | 3,485.04 | 3,667.05 | 3,527.91 | 3,303.49 | 3,247.57 | 4,267.47 | 4,305.52 | 3,637.23 | ||||||||||
| Interest & Other Items | 34.73 | 73.57 | 61.54 | 69.17 | 51.51 | 49.14 | 74.80 | 99.86 | 78.36 | 85.89 | ||||||||||
| PBT | 3,000.35 | 2,815.52 | 3,423.50 | 3,597.88 | 3,476.40 | 3,254.35 | 3,172.77 | 4,167.61 | 4,227.16 | 3,551.34 | ||||||||||
| Taxes & Other Items | 476.60 | 160.94 | 587.88 | 557.72 | 573.02 | 1,104.47 | 894.14 | 1,049.66 | 858.35 | 837.31 | ||||||||||
| Net Income | 2,523.75 | 2,654.58 | 2,835.62 | 3,040.16 | 2,903.38 | 2,149.88 | 2,278.63 | 3,117.95 | 3,368.81 | 2,714.03 | ||||||||||
| EPS | 10.50 | 11.10 | 11.80 | 12.70 | 12.10 | 9.00 | 9.50 | 13.00 | 14.00 | 11.30 |
SUNPHARMA Company Updates
Investor Presentation
SUNPHARMA Stock Peers
SUNPHARMA Past Performance & Peer Comparison
SUNPHARMA Past Performance & Peer Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 40.16 | 5.50 | 0.83% |
| Torrent Pharmaceuticals Ltd | 77.46 | 9.53 | 0.77% |
| Cipla Ltd | 29.71 | 3.34 | 0.91% |
| Lupin Ltd | 21.37 | 6.59 | 0.72% |
SUNPHARMA Stock Price Comparison
Compare SUNPHARMA with any stock or ETFSUNPHARMA Holdings
SUNPHARMA Shareholdings
SUNPHARMA Promoter Holdings Trend
SUNPHARMA Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
SUNPHARMA Institutional Holdings Trend
SUNPHARMA Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has almost stayed constant
SUNPHARMA Shareholding Pattern
SUNPHARMA Shareholding Pattern
SUNPHARMA Shareholding History
SUNPHARMA Shareholding History
Mutual Funds Invested in SUNPHARMA
Mutual Funds Invested in SUNPHARMA
No mutual funds holding trends are available
Top 5 Mutual Funds holding Sun Pharmaceutical Industries Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6206% | Percentage of the fund’s portfolio invested in the stock 4.79% | Change in the portfolio weight of the stock over the last 3 months -0.08% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 5/93 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4132% | Percentage of the fund’s portfolio invested in the stock 2.52% | Change in the portfolio weight of the stock over the last 3 months -0.29% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 11/104 (0) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.3994% | Percentage of the fund’s portfolio invested in the stock 3.60% | Change in the portfolio weight of the stock over the last 3 months -0.93% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 3/279 (+1) |
Compare 3-month MF holding change on Screener
smallcases containing SUNPHARMA stock
smallcases containing SUNPHARMA stock
A smallcase is a basket of stocks/ETFs that represents an idea or theme.Diversify your risk and buy smallcases that have Sun Pharmaceutical Industries Ltd
SUNPHARMA Events
SUNPHARMA Events
SUNPHARMA Dividend Trend
SUNPHARMA has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.83%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.33 every year
Dividends
Corp. Actions
Announcements
Legal Orders
SUNPHARMA Dividend Trend
SUNPHARMA has increased or maintained dividend levels over the last 5 years
Current dividend yield is 0.83%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹8.33 every year
SUNPHARMA Upcoming Dividends
SUNPHARMA Upcoming Dividends
No upcoming dividends are available
SUNPHARMA Past Dividends
SUNPHARMA Past Dividends
Cash Dividend
Ex DateEx DateJul 7, 2026
Dividend/Share
₹5.00
Ex DateEx Date
Jul 7, 2026
Cash Dividend
Ex DateEx DateFeb 5, 2026
Dividend/Share
₹11.00
Ex DateEx Date
Feb 5, 2026
Cash Dividend
Ex DateEx DateJul 7, 2025
Dividend/Share
₹5.50
Ex DateEx Date
Jul 7, 2025
Cash Dividend
Ex DateEx DateFeb 6, 2025
Dividend/Share
₹10.50
Ex DateEx Date
Feb 6, 2025
Cash Dividend
Ex DateEx DateJul 12, 2024
Dividend/Share
₹5.00
Ex DateEx Date
Jul 12, 2024
SUNPHARMA Stock News & Opinions
SUNPHARMA Stock News & Opinions
Sun Pharmaceuticals Industries will hold a meeting of the Board of Directors of the Company on 31 July 2026.
Sun Pharmaceutical Industries Ltd rose for a fifth straight session today. The stock is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 24472.4. The Sensex is at 78420.16, up 0.17%. Sun Pharmaceutical Industries Ltd has added around 7.01% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has added around 6.88% in last one month and is currently quoting at 25866.25, down 0.22% on the day. The volume in the stock stood at 10.77 lakh shares today, compared to the daily average of 19.54 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1917.1, down 0.05% on the day. Sun Pharmaceutical Industries Ltd is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma index.The PE of the stock is 152.92 based on TTM earnings ending March 26.Powered by Capital Market - Live
Sun Pharmaceutical Industries Ltd is up for a third straight session in a row. The stock is quoting at Rs 1911.1, up 2.14% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.74% on the day, quoting at 24354.25. The Sensex is at 78056.84, up 0.72%. Sun Pharmaceutical Industries Ltd has risen around 7.36% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 6.77% in last one month and is currently quoting at 25308.9, up 2% on the day. The volume in the stock stood at 15.41 lakh shares today, compared to the daily average of 20.27 lakh shares in last one month. The benchmark July futures contract for the stock is quoting at Rs 1915.8, up 2.17% on the day. Sun Pharmaceutical Industries Ltd is up 14.01% in last one year as compared to a 4.35% drop in NIFTY and a 15.33% drop in the Nifty Pharma index.The PE of the stock is 149.6 based on TTM earnings ending March 26.Powered by Capital Market - Live
Sun Pharmaceutical Industries Ltd gained for a fifth straight session today. The stock is quoting at Rs 1885, up 1.19% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.64% on the day, quoting at 23948.45. The Sensex is at 76610.4, down 0.63%. Sun Pharmaceutical Industries Ltd has risen around 2.41% in last one month. Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has risen around 1.62% in last one month and is currently quoting at 24762.9, up 1.26% on the day. The volume in the stock stood at 16.35 lakh shares today, compared to the daily average of 26.88 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1883.8, up 1.11% on the day. Sun Pharmaceutical Industries Ltd is up 13.44% in last one year as compared to a 4.38% drop in NIFTY and a 15.7% drop in the Nifty Pharma index.The PE of the stock is 148.96 based on TTM earnings ending March 26.Powered by Capital Market - Live
Innovcare Lifesciences is engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The revenue from operations for FY 2025-26 was Rs 94.06 crore. Sun Pharma stated that this acquisition is being done to strengthen product portfolio of the company. The company expects to complete this transaction before 31 July 2026. Sun Pharmaceutical Industries is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and active pharmaceutical ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world, with trading and other incidental and related activities extending to global market. It is the largest pharmaceutical company in India. The company had reported 26.24% rise in consolidated net profit to Rs 2,714.03 crore in Q4 FY26 as against Rs 2,149.88 crore posted in the same period year ago. Total revenue from operations increased 12.75% YoY to Rs 14,611.79 crore in the quarter ended 31 March 2026. The scrip advanced 0.85% to currently trade at Rs 1852.70 on the BSE. Powered by Capital Market - Live
Securities in F&O Ban: Shares of Kaynes Technology India are banned from F&O trading on 22 June 2026. Stocks to Watch: Sun Pharmaceuticals Industries has entered into an agreement to acquire 100% stake in Innovcare Lifesciences, based in Mumbai and engaged in the business of marketing, distribution and sale of pharmaceutical drugs, nutraceutical and cosmeceutical products. The total consideration of the transaction is valued at Rs 271.2 crore. Garden Reach Shipbuilders & Engineers (GRSE) has been granted Navratna status by the Department of Public Enterprises (DPE) under the Ministry of Finance. The company said the recognition reflects its strong financial performance, operational efficiency and contribution to national security. GE Power India announced a series of senior leadership changes, including the appointment of Rahul Rojal as Chief Financial Officer (CFO), as the company strengthens its management team amid ongoing business and project execution initiatives. Goodluck India announced that its subsidiary, Goodluck Defence and Aerospace, has secured an order worth approximately Rs 255 crore for the supply of 155 mm long-range empty shells in ready-to-fill condition. Zaggle Prepaid Ocean Services (Zaggle) announced that it has entered into an agreement with Punjab National Bank (PNB) to act as a co-branding partner for a retail credit card product. Under the agreement, Zaggle will leverage its existing corporate customer base to drive acquisition, marketing and promotion of the co-branded retail credit card. The partnership is aimed at expanding the reach of the co-branded card offering. Texmaco Rail & Engineering has received a letter of intent (LoI) worth Rs 253.28 crore from JSW (South) Rail Logistics for the manufacture and supply of BFNSM1 rakes along with BVCM wagons. The domestic order is scheduled to be executed within 13.5 months from the effective date or commencement of work.Powered by Capital Market - Live
Sun Pharmaceuticals Industries announced that the 34th Annual General Meeting(AGM) of the company will be held on 31 July 2026.
Sun Pharmaceutical Industries has fixed 07 July 2026 as record date for determining the entitlement of shareholders to receive the final dividend of Rs 5 per equity share for the financial year 20225-26. The payment of the said final dividend, if approved by the shareholders at the AGM, will be made on or before 07 August 2026
Sun Pharmaceutical Industries Ltd fell for a fifth straight session today. The stock is quoting at Rs 1774.1, down 0.81% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 0.22% on the day, quoting at 23353.3. The Sensex is at 74101.32, down 0.33%.Sun Pharmaceutical Industries Ltd has eased around 2.56% in last one month.Meanwhile, Nifty Pharma index of which Sun Pharmaceutical Industries Ltd is a constituent, has increased around 2.59% in last one month and is currently quoting at 24086.6, up 0.38% on the day. The volume in the stock stood at 11.66 lakh shares today, compared to the daily average of 29.77 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1793.9, down 0.5% on the day. Sun Pharmaceutical Industries Ltd jumped 5.41% in last one year as compared to a 5.65% slide in NIFTY and a 11.71% spurt in the Nifty Pharma index.The PE of the stock is 143.04 based on TTM earnings ending March 26.Powered by Capital Market - Live
Sun Pharmaceuticals Industries announced that the Board of Directors of the Company at its meeting held on 22 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

Over the last 5 years, revenue has grown at a yearly rate of 12.41%, vs industry avg of 12.43%
Over the last 5 years, market share decreased from 12.19% to 12.08%
Over the last 5 years, net income has grown at a yearly rate of 31.64%, vs industry avg of 10.55%